Inductive Bio, a NYC-based technology company advancing artificial intelligence (AI) models for small molecule drug discovery, raised $25M in Series A funding.
The round was led by Obvious Ventures with participation from Andreessen Horowitz (a16z) Bio + Health, Lux Capital, S32, Character, and Amino Collective, alongside angel investors including Oren Etzioni, Jeff Hammerbacher, Malay Gandhi, and Jakob Uszkoreit.
The company intends to use the funds to expand its AI model R&D, and grow its pre-competitive data consortium.
Led by CEO Josh Haimson, Inductive Bio has developed a collaborative AI platform that accelerates compound optimization. By building a pre-competitive data consortium and ML models designed to map the drivers of small molecule Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET), its platform allows scientists to optimize initial compounds into leads and development candidates faster and with a better balance of ADMET properties.
In a recent collaboration with Nested Therapeutics, published in ACS Medicinal Chemistry Letters, the platform helped resolve permeability and metabolic stability issues, contributing to the nomination of a drug development candidate with cell potency and cross-species pharmacokinetics.
FinSMEs
07/05/2025